Remove stage
article thumbnail

The Stages of Shingles

Drug Topics

The clinical manifestations of shingles can be divided into 3 phases.

187
187
article thumbnail

Nuvation Bio nears commercial stage with AnHeart buy

pharmaphorum

Nuvation Bio speeds up its path to becoming a commercial-stage biotech with a deal to acquire AnHeart Therapeutics and its late-stage lung cancer therapy taletrectinib

109
109
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA Approves Nivolumab for Completely Resected Stage IIB or Stage IIC Melanoma in Adult, Pediatric Patients

Pharmacy Times

In clinical trials, nivolumab (Opdivo) demonstrated a statistically significant improvement in recurrence-free survival compared to placebo in eligible patients with stages IIB, IIC, III, and stage IV completely resected melanoma.

FDA 122
article thumbnail

Enhancing Breast Cancer Treatment: Expanding CDK4/6 Inhibitor Use in the Early-Stage Setting

Pharmacy Times

Danielle Roman, PharmD, BCOP, discusses the efficacy and safety outcomes of CDK4/6 inhibitors in early-stage breast cancer, as well as key considerations for CDK4/6 inhibitors in this indication.

107
107
article thumbnail

The Role of Oncology Pharmacists Is Evolving in Early-Stage Breast Cancer Treatment Optimization

Pharmacy Times

Danielle Roman, PharmD, BCOP, discusses how the role of the oncology pharmacist has changed in recent years in optimizing early-stage breast cancer treatment with targeted therapies.

99
article thumbnail

Takeda grabs late-stage haematology drug from Protagonist

pharmaphorum

Takeda licenses late-stage polycythemia vera drug candidate rusfertide from Protagonist Therapeutics, adding to its rare blood disorder pipeline.

99
article thumbnail

Boehringer Ingelheim leans on late-stage pipeline, plots 25 new launches over the next decade

Fierce Pharma

The company's late-stage pipeline focuses on oncology, cardiorespiratory diseases, mental health and cardiovascular-renal-metabolic conditions. Boehringer Ingelheim’s 2023 was largely marked by the highly anticipated launch of its Cyltezo, the first interchangeable biosimilar to AbbVie’s Humira. |

85